Pfizer Earnings Expected to Fall 16% Ahead
Healthcare suppliers and pharmacy-adjacent businesses should watch how Pfizer's cost cuts respond to expiring drug patents.
Updated on Nov. 2, 2026 in Healthcare
Pfizer is scheduled to release its third-quarter report before U.S. markets open on Tuesday, November 3, 2026, with analysts estimating earnings per share at 73 cents, down 16%, and revenue near $15.88 billion, down 4.6%. Operators tracking healthcare pricing and drug supply should note the report will shape expectations for the company's cost-cutting program.
Why it matters
Analyst estimates are forecasts compiled ahead of the release, not reported results, so the figures signal what the market expects rather than what the company has delivered. Investors are focused on whether the cost-cutting program and the approaching loss of exclusivity for Eliquis, Ibrance, and Xtandi will reshape the company's revenue base.
Analysts estimate Pfizer's third-quarter earnings per share at 73 cents, down 16%, and revenue at $15.88 billion, down 4.6%, based on pre-report forecasts. These are consensus estimates rather than reported results, and the actual figures will be published when the company releases its quarter.
The players
Pfizer
A large global pharmaceutical company whose business spans branded medicines, vaccines, and biosimilars, and which is navigating patent expirations on several top-selling drugs.
Metsera
A biotechnology company whose anti-obesity drug candidate has become a point of investor interest for Pfizer's future pipeline.
The details
Pfizer's revenue outlook depends on its ability to offset the expected erosion from several major products losing exclusivity, meaning the period of market protection that keeps generic competitors out. Eliquis, Ibrance, and Xtandi are approaching that point, and the company's cost-cutting program is the lever management is using to protect margins during the transition. Investors will also watch an anti-obesity candidate tied to the Metsera acquisition, which has drawn attention as a potential future growth driver.
Timeline
Tuesday, November 3, 2026: Pfizer releases its third-quarter report before U.S. markets open.
2028 to 2033: Pfizer management projects high single-digit growth over this period.
Next 10 years: Analysts expect no growth over this period.
Market Landscape
Pfizer's report arrives as several of its largest brand-name drugs approach loss of exclusivity, a pattern that forces branded drugmakers to replace falling revenue with new products or cost reductions. The company's projection of high single-digit growth from 2028 to 2033 contrasts with analyst expectations of no growth over the next decade, leaving the gap between management's outlook and the market's skepticism as a central question.
Operators in healthcare supply chains and pharmacy-adjacent businesses should watch whether Pfizer's cost-cutting translates into changes in pricing, contracting, or product availability. Businesses that depend on the company's branded products should monitor how the loss of exclusivity for major drugs affects generic availability and reimbursement terms over the coming year.
The takeaway
The key operating signal is that branded drugmakers rely on cost reduction and new pipeline products to offset patent expirations, so the November 3 report will show how much of that replacement is already visible. Operators should track the company's reported revenue against the $15.88 billion estimate and review any guidance changes for the 2028 to 2033 growth outlook when the filing is published.
What happens next
Pfizer releases its third-quarter report before U.S. markets open on Tuesday, November 3, 2026, when actual results will replace the analyst estimates discussed here.
Further reading
For broader context on how drug patent expirations reshape pharmaceutical revenue, see more coverage in our Healthcare section.
